FROM PUBLIC EVENTS · 2026-11-18

Current stage

  1. Discovery · preclinical
  2. Early clinical · first deals
  3. Late clinical · capacity
  4. Commercial · sales
  1. Global approvals · expansion
  2. M&A · integration
  3. Pipeline reshaping

Early clinical · first deals A licensed candidate has entered Phase 1, and partnered development of its bispecific ADC has widened.

  • GC Corp exercised its bispecific ADC co-development option. Source
  • Listed on KOSDAQ. Source

Roles often seen at this stageResearch & development · BD & licensing · Clinical & PV

Companies at the same stage and their people flow →

← Company library
Korea / Company briefSources checked 2026-11-18

Kanaph Therapeutics

A drug developer founded in February 2019 that works on bispecific immuno-oncology antibodies and ADCs aimed at the tumor microenvironment; listed on KOSDAQ in March 2026.

KNP-502 (OCT-598)

Phase 1

An EP2/EP4 inhibitor licensed to Oscotec; dosing in a Phase 1 solid-tumor trial began in late 2025.

KNP-701

Stage unconfirmed

A bispecific ADC targeting both EGFR and cMET; GC Corp exercised its co-development option, and Kanaph leads CMC development.

KNP-301

Stage unconfirmed

A preclinical bispecific antibody for macular degeneration targeting C3b and VEGF.

KNP-101

Stage unconfirmed

A cancer candidate built as a fusion protein of FAP and a modified IL-12.

Completion reported

GC Corp exercised its option to co-develop the EGFR/cMET bispecific ADC.

Official role guide

Kanaph Therapeutics careers

Current availability unconfirmed

Observed 2026-11-18

Work
Unconfirmed — The official careers page could not be confirmed.
Experience & requirements
Unconfirmed — The official careers page could not be confirmed.

Information from a role guide does not establish a current vacancy.

Sources & coverage 2

A brief based on selected official material, not an exhaustive product or vacancy list.

  1. [BioS]카나프테라퓨틱스, 상장 첫날 '154.5% 급등' 마감 ↗이투데이 · Published 2026-03-16 · Sources checked 2026-11-18 · Original unavailable
  2. GC녹십자 - 카나프테라퓨틱스, 이중항체 ADC 신약 개발 옵션 행사 확정 ↗GC녹십자 · Published 2025-12-18 · Sources checked 2026-11-18 · Original unavailable